NanoViricides (NNVC) vs Rockwell Medical (RMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NanoViricides (NNVC) has outperformed Rockwell Medical (RMTI) over the past year, gaining 1.4% versus a loss of 33.7%. Over five years, NNVC leads with a -70.5% price change compared with -87.8% for RMTI. NanoViricides is the larger company by market cap ($33.4 million vs $32.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNVC | RMTI |
|---|---|---|
| Share price | $1.31 | $8.02 |
| Market cap | $33.44M | $32.32M |
| 1-day change | -9.03% | -2.43% |
| YTD return | +27.43% | -3.37% |
| 1-year return | +1.41% | -33.72% |
| 5-year return | -70.49% | -87.85% |
| Forward P/E | — | 114.57 |
| EPS (TTM) | $-0.41 | $-1.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.23 | $12.90 |
| 52-week low | $0.85 | $4.89 |
| Distance from 52-week high | -41.26% | -37.83% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +358.02% | +149.38% |
| Average volume | 445.00K | 26.80K |
| Shares outstanding | 25.52M | 4.03M |
| Employees | 7 | 157 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed RMTI by 35.1 percentage points over the past year.
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Healthcare · Biotechnology · 7 employees
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Healthcare · Drug Manufacturers - Specialty & Generic · 157 employees
NNVC vs RMTI FAQ
Which is bigger, NanoViricides or Rockwell Medical?
NanoViricides (NNVC) is larger, with a market capitalization of $33.44M compared with $32.32M for Rockwell Medical (RMTI).
Which stock has performed better over the past year, NNVC or RMTI?
NNVC returned +1.41% over the past 12 months, compared with -33.72% for RMTI (price return, excluding dividends). Past performance does not predict future results.
Are NanoViricides and Rockwell Medical in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for NanoViricides and Drug Manufacturers - Specialty & Generic for Rockwell Medical.